Category - Feature

Feature

Ciclofilin developing first drug for HCV/HIV-1 co-infection

By Len Zehr Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...

June 24, 2014

Feature

Mati Therapeutics isn’t your traditional biotech startup

By Len Zehr Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye...

June 10, 2014

Feature

Opexa is personalizing the treatment of autoimmune disease

By Len Zehr With its Phase 2b clinical trial in secondary-progressive multiple sclerosis (SPMS) running nicely, Opexa Therapeutics (NASDAQ:OPXA) is considering adding a new disease indication to its antigen-specific T...

June 3, 2014

Feature

Enrollment in Athersys stroke trial nears completion

By Len Zehr Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients...

May 27, 2014

Feature

Knight won’t rest til it bests Paladin

By Len Zehr “It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty...

May 13, 2014

Feature

In conversation with Alistair Duncan

By Len Zehr As a co-founder, president and CEO of closely held viDA Therapeutics, a tissue repair company, Alistair Duncan has developed an affinity for doing biotech startups. From 1998 to 2008, he was president and...

May 6, 2014

Feature

Microbix focus squarely on LumiSort and diagnostic products

By Len Zehr So says Vaughn Embro-Pantalony, president and CEO of Microbix Biosystems (TSX:MBX), referring to the company’s livestock semen sexing technology, LumiSort, and its manufacturing of infectious disease...

April 29, 2014

Feature

Aurinia to begin lupus nephritis trial at end of April

By Len Zehr Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin...

April 15, 2014

Feature

Gour Medical in talks to expand animal health portfolio

By Len Zehr Upstart Gour Medical Animal Health, which recently agreed to acquire a portfolio of four products to be reformulated for pet care, is also negotiating for three or four additional products. “We are...

April 8, 2014

Feature

MRI Interventions’ ClearPoint changing brain surgery paradigm

By Len Zehr “Our goal is to transform the way brain surgery is performed to advance better treatment options for patients for whom current therapies are deficient.” So says Kimble Jenkins, CEO of MRI Interventions...

March 25, 2014

Category - Feature

Subscribe